Every 10-Q that Perspective Therapeutics, Inc. (CATX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CATX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CATX filings page.
Perspective Therapeutics, Inc. is a clinical-stage radiopharmaceutical company advancing multiple Lead-212–based cancer programs while significantly building its manufacturing and financial base. As of June 30, 2026, it held $48.5 million in cash and cash equivalents and $188.4 million in short‑term available‑for‑sale securities, for total cash, cash equivalents and short‑term investments of $236.9 million. Management believes this will fund current planned operations into late 2027.
For the six months ended June 30, 2026, grant revenue was $0.2 million and the net loss widened to $53.0 million from $39.7 million a year earlier, driven primarily by higher research and development expense of $42.9 million and continued build‑out of capabilities. The company completed a large underwritten equity financing and pre‑funded warrant issuance in February 2026, raising gross proceeds of approximately $175.0 million, and ended the period with $323.9 million of stockholders’ equity and an accumulated deficit of $387.8 million.
Perspective is progressing three core clinical programs (VMT‑α‑NET, VMT01 and PSV359), expanding a distributed manufacturing network including a Somerset, New Jersey facility and new sites in Houston, Chicago and Los Angeles, and has committed to significant equipment and construction spending and a DOE thorium‑228 supply agreement as it prepares for later‑stage trials and potential commercialization.
Perspective Therapeutics reported a larger net loss as it ramped up development of its radiopharmaceutical pipeline in the quarter ended March 31, 2026. Net loss was $26.2 million, or $0.25 per share, compared with $18.2 million a year earlier, driven mainly by higher research and development spending.
Research and development expense rose to $21.4 million from $14.3 million as the company advanced its VMT-α-NET, VMT01 and PSV359 clinical programs and expanded manufacturing capacity. General and administrative costs eased slightly to $7.0 million from $7.8 million.
Cash, cash equivalents and short-term investments reached $270.9 million, helped by a February 2026 underwritten offering that generated about $175.0 million in gross proceeds. Management believes this cash position can fund planned operations and clinical milestones into late 2027 while it continues to invest in facilities and equipment for future commercial-scale production.
Perspective Therapeutics (CATX) reported Q3 2025 results showing continued investment in its radiopharmaceutical pipeline. The company recorded a net loss of $25.969 million (loss per share $0.35) on $209 thousand of grant revenue. Operating expenses were driven by R&D of $20.339 million and G&A of $7.731 million, resulting in an operating loss of $27.861 million.
Liquidity remains solid with $174.1 million in cash, cash equivalents and short‑term investments as of September 30, 2025, which the company believes will fund current plans into late 2026. Year‑to‑date, operating cash outflows were $57.827 million, partially offset by $12.691 million from investing activities and $10.318 million from financing, including $9.986 million raised via the at‑the‑market program in February 2025.
Common shares outstanding were 74,337,990 as of November 6, 2025. The company continues Phase 1/2a work across VMT‑α‑NET, VMT01 and PSV359 while building out manufacturing capacity to support clinical and future commercial supply.
Perspective Therapeutics, Inc. is a radiopharmaceutical developer focused on targeted alpha therapies. At June 30, 2025 the company reported $28.85 million in cash and $162.73 million in short-term investments (combined $191.6 million), and management believes these resources will fund current planned operations into late 2026.
Operating spending rose notably year-over-year as R&D increased to $30.95 million for the six months ended June 30, 2025 and total operating expenses were $46.50 million, producing a six-month net loss of $39.66 million. The balance sheet shows total assets of $310.7 million, an accumulated deficit of $271.4 million and 74,262,990 common shares outstanding (per the filing).
Clinical progress reported: opening of Cohort 3 for [212Pb]VMT-α-NET (Cohort 2 had 46 patients treated), FDA "study may proceed" for PSV359 with two patients treated as of July 31, 2025, and Fast Track designation for [212Pb]VMT01. The company also reported recent patent grants and continued investments in manufacturing capacity.